Lake Street assumed coverage of P3 Health Partners (PIII) with a Buy rating and $20 price target Despite first half revenue declining versus the prior year, Q2 results showed “encouraging signs,” the analyst tells investors. 2025 remains a transitional year as the P3 sets up for a “transformational 2026,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PIII: